From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis
Authors
Keywords
Interleukin-6, Cytokine signaling, Inflammatory bowel disease, Immunology, Ulcerative colitis, Crohn’s disease
Journal
ARCHIVES OF TOXICOLOGY
Volume 89, Issue 4, Pages 541-554
Publisher
Springer Nature
Online
2015-01-29
DOI
10.1007/s00204-015-1461-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma
- (2014) Robert Z. Orlowski et al. AMERICAN JOURNAL OF HEMATOLOGY
- Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study
- (2014) Mark C Genovese et al. ANNALS OF THE RHEUMATIC DISEASES
- Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy
- (2014) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN)
- (2014) Joachim Sieper et al. ANNALS OF THE RHEUMATIC DISEASES
- IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab
- (2014) Yoshiya Tanaka et al. ANNALS OF THE RHEUMATIC DISEASES
- Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma
- (2014) J. San-Miguel et al. BLOOD
- Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors
- (2014) Johanna C. Bendell et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors
- (2014) E. Angevin et al. CLINICAL CANCER RESEARCH
- Sirukumab: a novel therapy for lupus nephritis?
- (2014) Uma Thanarajasingam et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Regulation of IL-17 in Human CCR6+ Effector Memory T Cells
- (2014) H. Liu et al. JOURNAL OF IMMUNOLOGY
- Discovery and characterization of olokizumab
- (2014) Stevan Shaw et al. mAbs
- Regulatory B cells are induced by gut microbiota–driven interleukin-1β and interleukin-6 production
- (2014) Elizabeth C Rosser et al. NATURE MEDICINE
- IL-6 biology: implications for clinical targeting in rheumatic disease
- (2014) Leonard H. Calabrese et al. Nature Reviews Rheumatology
- Master regulator of intestinal disease: IL-6 in chronic inflammation and cancer development
- (2014) Maximilian J. Waldner et al. SEMINARS IN IMMUNOLOGY
- IL-6 and related cytokines as the critical lynchpins between inflammation and cancer
- (2014) Koji Taniguchi et al. SEMINARS IN IMMUNOLOGY
- A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy
- (2014) Toshio Tanaka et al. SEMINARS IN IMMUNOLOGY
- IL-6 in Inflammation, Immunity, and Disease
- (2014) T. Tanaka et al. Cold Spring Harbor Perspectives in Biology
- Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial
- (2013) Tom W J Huizinga et al. ANNALS OF THE RHEUMATIC DISEASES
- A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma
- (2013) Peter M. Voorhees et al. BRITISH JOURNAL OF HAEMATOLOGY
- OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells
- (2013) Mi-Jung Kim et al. CANCER LETTERS
- gp130: a promising drug target for cancer therapy
- (2013) Shili Xu et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
- (2013) Cem Gabay et al. LANCET
- Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study
- (2013) Norihiro Nishimoto et al. Modern Rheumatology
- A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases
- (2013) F Hayakawa et al. Blood Cancer Journal
- A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate
- (2012) P Mease et al. ANNALS OF THE RHEUMATIC DISEASES
- Ruxolitinib: The First FDA Approved Therapy for the Treatment of Myelofibrosis
- (2012) J. Mascarenhas et al. CLINICAL CANCER RESEARCH
- Therapeutic Blockade of Interleukin-6 in Chronic Inflammatory Disease
- (2012) K Yamamoto et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer
- (2012) Gary Hudes et al. INVESTIGATIONAL NEW DRUGS
- First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy
- (2012) Malabika Sen et al. Cancer Discovery
- Therapeutic Targeting of the Interleukin-6 Receptor
- (2011) Toshio Tanaka et al. Annual Review of Pharmacology and Toxicology
- IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer
- (2011) Markus F. Neurath et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer
- (2011) K. Fizazi et al. EUROPEAN JOURNAL OF CANCER
- A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer
- (2011) Trevor J Bayliss et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling
- (2011) Simon A. Jones et al. JOURNAL OF CLINICAL INVESTIGATION
- Identification of IL6R and chromosome 11q13.5 as risk loci for asthma
- (2011) Manuel AR Ferreira et al. LANCET
- The acute phase protein response in patients receiving subcutaneous IL-6
- (2010) R. E. BANKS et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- IL-6: Regulator of Treg/Th17 balance
- (2010) Akihiro Kimura et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Anti-IL-6 receptor antibody suppressed T cell activation by inhibiting IL-2 production and inducing regulatory T cells
- (2010) Hiroto Yoshida et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Tocilizumab for the treatment of rheumatoid arthritis
- (2010) Toshio Tanaka et al. Expert Review of Clinical Immunology
- Comparative analysis of the effects of anti-IL-6 receptor mAb and anti-TNF mAb treatment on CD4+ T-cell responses in murine colitis
- (2010) Fumitaka Terabe et al. INFLAMMATORY BOWEL DISEASES
- Induction of tolerogenic lung CD4+ T cells by local treatment with a pSTAT-3 and pSTAT-5 inhibitor ameliorated experimental allergic asthma
- (2010) Michael Hausding et al. INTERNATIONAL IMMUNOLOGY
- Th17 cells in inflammation
- (2010) Akihiro Kimura et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation
- (2010) Shigeru Kotake et al. JOURNAL OF BONE AND MINERAL RESEARCH
- VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer
- (2010) Maximilian J. Waldner et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Although IL-6 Trans-Signaling Is Sufficient To Drive Local Immune Responses, Classical IL-6 Signaling Is Obligate for the Induction of T Cell-Mediated Autoimmunity
- (2010) R. Lissilaa et al. JOURNAL OF IMMUNOLOGY
- The Influence of Excessive IL-6 Production In Vivo on the Development and Function of Foxp3+ Regulatory T Cells
- (2010) M. Fujimoto et al. JOURNAL OF IMMUNOLOGY
- Sputum IL-6 concentrations in severe asthma and its relationship with FEV1
- (2010) J. B. Morjaria et al. THORAX
- gp130-Mediated Stat3 Activation in Enterocytes Regulates Cell Survival and Cell-Cycle Progression during Colitis-Associated Tumorigenesis
- (2009) Julia Bollrath et al. CANCER CELL
- IL-6 and Stat3 Are Required for Survival of Intestinal Epithelial Cells and Development of Colitis-Associated Cancer
- (2009) Sergei Grivennikov et al. CANCER CELL
- Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis
- (2009) Y. Li et al. GUT
- The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4+T cells
- (2009) Oliver Dienz et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Essential Roles of IL-6 Trans-Signaling in Colonic Epithelial Cells, Induced by the IL-6/Soluble-IL-6 Receptor Derived from Lamina Propria Macrophages, on the Development of Colitis-Associated Premalignant Cancer in a Murine Model
- (2009) S. Matsumoto et al. JOURNAL OF IMMUNOLOGY
- Properties and origin of human Th17 cells
- (2009) Sergio Romagnani et al. MOLECULAR IMMUNOLOGY
- Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis
- (2009) T. Yoshimura et al. RHEUMATOLOGY
- The effects of adalimumab and methotrexate treatment on peripheral Th17 cells and IL-17/IL-6 secretion in rheumatoid arthritis patients
- (2009) Cai Yue et al. RHEUMATOLOGY INTERNATIONAL
- Anti-inflammatory mechanism of tocilizumab, a humanized anti-IL-6R antibody: effect on the expression of chemokine and adhesion molecule
- (2009) Miho Suzuki et al. RHEUMATOLOGY INTERNATIONAL
- Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study
- (2008) N Nishimoto et al. ANNALS OF THE RHEUMATIC DISEASES
- Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses
- (2008) Minoru Fujimoto et al. ARTHRITIS AND RHEUMATISM
- Crucial role of the interleukin-6/interleukin-17 cytokine axis in the induction of arthritis by glucose-6-phosphate isomerase
- (2008) Keiichi Iwanami et al. ARTHRITIS AND RHEUMATISM
- Arthritis and pneumonitis produced by the same T cell clones from mice with spontaneous autoimmune arthritis
- (2008) Chiaki Wakasa-Morimoto et al. INTERNATIONAL IMMUNOLOGY
- The transcription factor NFATc2 controls IL-6–dependent T cell activation in experimental colitis
- (2008) Benno Weigmann et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial
- (2008) Shumpei Yokota et al. LANCET
- Lower Airway Disease in Asthmatics with and without Rhinitis
- (2008) Anne E. Dixon et al. LUNG
- The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer
- (2008) Willscott E. Naugler et al. TRENDS IN MOLECULAR MEDICINE
- A Genome-Wide Association Study Identifies Protein Quantitative Trait Loci (pQTLs)
- (2008) David Melzer et al. PLoS Genetics
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started